Phathom Pharmaceuticals (PHAT) Asset Writedowns and Impairment (2024 - 2025)
Phathom Pharmaceuticals' (PHAT) quarterly Asset Writedowns and Impairment came in at -$539000.0 in Q4 2025, down 549.17% year-on-year from $120000.0 in Q4 2024, and down 573.75% on a QoQ basis from -$80000.0 in Q2 2025.
Phathom Pharmaceuticals (PHAT) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 2 years of Asset Writedowns and Impairment data on file, last reported at -$539000.0 in Q4 2025.
- On a quarterly basis, Asset Writedowns and Impairment fell 549.17% year-over-year to -$539000.0 in Q4 2025; TTM through Mar 2026 was -$619000.0, a 135.68% decrease from a year earlier, with the FY2025 full-year figure at $280000.0, down 66.51% from the prior year.
- Asset Writedowns and Impairment for Q4 2025 stood at -$539000.0, down from -$80000.0 in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for PHAT reached as high as $899000.0 in Q1 2025 and fell as low as -$539000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - |
| 10 | Phathom Pharmaceuticals | 983.79 Mn | 800.02 Mn | 46.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -539,000.00 |
| Dec 31, 2025 | -539,000.00 |
| Jun 30, 2025 | -80,000.00 |
| Jun 30, 2025 | -80,000.00 |
| Mar 31, 2025 | 899,000.00 |
| Mar 31, 2025 | 899,000.00 |
| Dec 31, 2024 | 120,000.00 |
| Dec 31, 2024 | 120,000.00 |
| Sep 30, 2024 | 473,000.00 |
| Sep 30, 2024 | 473,000.00 |
| Jun 30, 2024 | 243,000.00 |
| Jun 30, 2024 | 243,000.00 |